These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22237201)

  • 1. Why is the sustained virological response rate among HCV genotype 3 infected patients in Pakistan low?
    Qureshi S; Shafiei-Guilani M; Aalaei-Andabili SH
    J Coll Physicians Surg Pak; 2012 Jan; 22(1):70-1; author reply 71. PubMed ID: 22237201
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

  • 3. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
    Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
    Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB; Dusheiko GM; Tong MJ; Hollinger FB; Heathcote EJ; McHutchison J; Albert D
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
    Kurosaki M; Sakamoto N; Iwasaki M; Sakamoto M; Suzuki Y; Hiramatsu N; Sugauchi F; Tamori A; Nakagawa M; Izumi N
    J Med Virol; 2011 Mar; 83(3):445-52. PubMed ID: 21264865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
    Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
    de Bruijne J; Bergmann JF; Reesink HW; Weegink CJ; Molenkamp R; Schinkel J; Tong X; Li J; Treitel MA; Hughes EA; van Lier JJ; van Vliet AA; Janssen HL; de Knegt RJ
    Hepatology; 2010 Nov; 52(5):1590-9. PubMed ID: 20938912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
    Fan XH; Wang LF; Liu LC; Yao Y; Shan Y; Lu HY; Wu CH; Xu XY; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):721-5. PubMed ID: 22409840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
    J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
    Rumi MG; Aghemo A; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2007; 12(7):1033-40. PubMed ID: 18018761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha.
    Antonelli G; Riva E; Maggi F; Vatteroni ML; Simeoni E
    J Infect Dis; 1999 Oct; 180(4):1411-2. PubMed ID: 10479188
    [No Abstract]   [Full Text] [Related]  

  • 18. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
    Hui CK; Yuen MF; Sablon E; Chan AO; Wong BC; Lai CL
    J Infect Dis; 2003 Apr; 187(7):1071-4. PubMed ID: 12660921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.